Alerted this at .26 and it will gain 500%... eventually... look this is not in bio.
6bncr2mq2z
Posts
-
-
Why? This is tanked.
-
A great news from the company got wasted.
-
Lot of positive news patient approved and huge catalyst s from analysts with an average of $5.5. -
We are going to fly soon.
-
Lake Street Capital initiated Brickell Biotech (BBI +17.2%) with a Buy rating and price target of $6 indicating more than five-folds increase from current levels.
Analyst Thomas Flaten believes that the company has rapidly advanced its lead development program to Phase 3 readiness since becoming public via a reverse merger in 2019.
He further adds that he likes the odds of Brickell's treatment of primary axillary hyperhidrosis taking on Eli Lilly's Qbrexza in serving an underappreciated and under-treated disease state affecting a population of ~10M in the U.S.
Investor Presentation of Brickell states that it expects to initiate pivotal Phase 3 program in Q4; also there is a significant U.S. market opportunity in Hyperhidrosis which affects ~ 4.8% (15.3M) of U.S. population. $BBI -
Lake Street Capital initiated Brickell Biotech (BBI +17.2%) with a Buy rating and price target of $6 indicating more than five-folds increase from current levels.
Analyst Thomas Flaten believes that the company has rapidly advanced its lead development program to Phase 3 readiness since becoming public via a reverse merger in 2019.
He further adds that he likes the odds of Brickell's treatment of primary axillary hyperhidrosis taking on Eli Lilly's Qbrexza in serving an underappreciated and under-treated disease state affecting a population of ~10M in the U.S.
Investor Presentation of Brickell states that it expects to initiate pivotal Phase 3 program in Q4; also there is a significant U.S. market opportunity in Hyperhidrosis which affects ~ 4.8% (15.3M) of U.S. population. $BBI -
Lake Street Capital initiated Brickell Biotech (BBI +17.2%) with a Buy rating and price target of $6 indicating more than five-folds increase from current levels.
Analyst Thomas Flaten believes that the company has rapidly advanced its lead development program to Phase 3 readiness since becoming public via a reverse merger in 2019.
He further adds that he likes the odds of Brickell's treatment of primary axillary hyperhidrosis taking on Eli Lilly's Qbrexza in serving an underappreciated and under-treated disease state affecting a population of ~10M in the U.S.
Investor Presentation of Brickell states that it expects to initiate pivotal Phase 3 program in Q4; also there is a significant U.S. market opportunity in Hyperhidrosis which affects ~ 4.8% (15.3M) of U.S. population. $BBI -
Any positive news ... to fly some.....🥺
-
I shit not going anywhere... till September...... and boom... the we will see atleast 2$ ... have wait long....
-
This Hindenburg guys ruined many other companies.Long way of the story. They just can’t fuck the reality.
-
All is good . Just couple of speed breaks. After that its only highway🤩🤩🤩. Grass i green on the other side.
-
Run forest run🤩🤪
-
Nice dip in cidm. Join now for sky high🤩🤩🤩
-
Nice dip in cidm. Join now for sky high🤩🤩🤩
-
Excited for after hours volume!
-
I like that little squeeze 🤪
-
Hey ! I scanning news for buy out news.!!!!
-
All this is fucking trap! Stock going down... we definitely will get rid of it . Then boob news pops up. Again fucked up.
-
East or west @SRNE IS THE Best.
SHLO
AKBA
TTOO
BBI
BBI
BBI
BBI
BBI
BBI
IDEX
IDEX
IDEX
IDEX
VISL
GNUS
CIDM
CIDM
MVIS
SRNE
SRNE